Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli

J Nephrol. 2016 Dec;29(6):775-782. doi: 10.1007/s40620-016-0296-3. Epub 2016 Mar 28.

Abstract

Background: The 12-lipoxygenase (12-LO) and angiotensin II (Ang II) interaction plays an important role in diabetic nephropathy (DN). Proteinuria in DN is associated with decreased slit diaphragm proteins including nephrin and P-cadherin. Therefore, we investigated whether Ang II type 1 receptor (AT1) blocker (ARB) regulates 12-LO activity and slit diaphragm protein expression in diabetic rat glomeruli.

Method: Glomeruli were isolated with the sieving method, and classified into small glomeruli (SG; 75-μm sieve) and large glomeruli (LG; 125-μm sieve).

Results: 12(S)-HETE, a lipid product of 12-LO, was increased by Ang II in the glomeruli. Infusion of 12(S)-HETE and Ang II significantly decreased nephrin expression in LG, but increased it in SG compared to control. Glomerular P-cadherin expression was reduced after Ang II and 12(S)-HETE treatment without differences between LG and SG. ARB did not influence glycemic levels but completely abolished the increases in 12(S)-HETE, AT1 expression, and proteinuria in diabetic rats. Nephrin expression was significantly reduced in LG but increased in SG in diabetic rats compared to control. P-cadherin expression decreased in both diabetic LG and SG. The abnormalities of nephrin and P-cadherin were partially but significantly reversed by ARB.

Conclusion: ARB potentially ameliorates DN via the up-regulation of glomerular nephrin and P-cadherin expression through the inhibition of 12-LO activation in the glomeruli of rats with DN.

Keywords: 12(S)-HETE; Angiotensin II; Diabetic nephropathy; Nephrin; P-cadherin.

MeSH terms

  • 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / metabolism
  • Angiotensin II / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Arachidonate 12-Lipoxygenase / metabolism*
  • Cadherins / metabolism*
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / enzymology
  • Diabetes Mellitus, Type 2 / chemically induced
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / enzymology
  • Diabetic Nephropathies / enzymology
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / prevention & control*
  • Diet, High-Fat
  • Kidney Glomerulus / drug effects*
  • Kidney Glomerulus / enzymology
  • Lipoxygenase Inhibitors / pharmacology*
  • Losartan / pharmacology*
  • Male
  • Membrane Proteins / metabolism*
  • Mice
  • Podocytes / drug effects
  • Podocytes / metabolism
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / drug effects*
  • Receptor, Angiotensin, Type 1 / metabolism
  • Renin-Angiotensin System / drug effects
  • Streptozocin

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Cadherins
  • Lipoxygenase Inhibitors
  • Membrane Proteins
  • Receptor, Angiotensin, Type 1
  • nephrin
  • Angiotensin II
  • 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
  • Streptozocin
  • Arachidonate 12-Lipoxygenase
  • Losartan